Novo Boosts Profit Outlook on Obesity Drug Demand

preview_player
Показать описание
Novo Nordisk CEO Lars Fruergaard Jorgensen discusses the drugmaker’s struggles to meet demand for its blockbuster obesity medicine Wegovy and when it may be launched in additional markets. He speaks on “The Pulse With Francine Lacqua.”
--------
Connect with us on...
Рекомендации по теме
Комментарии
Автор

It seems the Mayo Clinic is trying to recommend, but continuity of care is an issue even at Mayo Clinic.

LoudBreather